DAIICHI SANKYO GROUP
DAIICHI SANKYO GROUP, a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and the Americas. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the group has since achieved significant milestones, including advancements in oncology and cardiovascular treatments. Specialising in innovative medicines, DAIICHI SANKYO is renowned for its unique drug development capabilities, particularly in targeted therapies and biologics. The company’s commitment to research and development has positioned it as a leader in the pharmaceutical market, with notable achievements such as the successful launch of several blockbuster drugs. With a strong focus on improving patient outcomes, DAIICHI SANKYO continues to make strides in the healthcare sector, solidifying its reputation as a trusted name in pharmaceuticals.
DitchCarbon Score
How does DAIICHI SANKYO GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DAIICHI SANKYO GROUP's score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
DAIICHI SANKYO GROUP's reported carbon emissions
DAIICHI SANKYO GROUP, headquartered in Japan (JP), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges at this time. As a result, there are no specific initiatives or commitments to report regarding their carbon footprint or climate action strategies. The absence of emissions data and reduction initiatives suggests that DAIICHI SANKYO GROUP may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data, it is unclear how DAIICHI SANKYO GROUP plans to address its environmental impact moving forward.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DAIICHI SANKYO GROUP is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
